Suppr超能文献

评估接受实体器官移植的患者使用甲氧苄啶-磺胺甲恶唑预防机会性感染时诺卡菌感染的发生率。

Evaluation of the Incidence of Nocardia Infection in Solid Organ Transplant Recipients on Trimethoprim-Sulfamethoxazole for Opportunistic Infection Prophylaxis.

作者信息

Jung Regina, Au Jenny, Burnell Jacqueline, Diamond Adam, Shah Ishani, Ruggia-Check Christina

机构信息

Department of Pharmacy, Lahey Hospital & Medical Center, Burlington, MA, USA.

Department of Pharmacy, Temple University Hospital, Philadelphia, PA, USA.

出版信息

Ann Pharmacother. 2025 Jul;59(7):604-611. doi: 10.1177/10600280241302412. Epub 2024 Dec 10.

Abstract

BACKGROUND

Trimethoprim-sulfamethoxazole (TMP-SMX) is the preferred prophylactic agent for pneumonia (PJP) and toxoplasmosis after solid organ transplant (SOT). Compared with other agents, it has additional activity against species.

OBJECTIVE

The purpose of this study was to evaluate the incidence of infection in SOT patients receiving TMP-SMX or an alternative agent for opportunistic infection (OI) prophylaxis.

METHODS

This retrospective analysis included transplant recipients at a large urban medical center over a period of 4 years. All patients received either TMP-SMX or an alternative agent for PJP prophylaxis. The primary outcome was the incidence of infection within 24 months posttransplant. Secondary outcomes included resistance rates of isolates, usage rates of alternative prophylactic agents, reasons for using alternative agents, and rate of conversion from an alternative agent back to TMP-SMX.

RESULTS

A total of 791 adult SOT recipients who received PJP or toxoplasmosis prophylaxis were included. Mean age at transplantation was 60.9 years with the majority of patients being male (67.3%) lung transplant recipients (63.6%). TMP-SMX was the most commonly used initial prophylactic agent (84.6%), followed by atovaquone (15.4%). Of the 791 SOT recipients, 16 (2.0%) were diagnosed with nocardiosis within 24 months posttransplant. Patients receiving alternative agents had a higher incidence of infection compared with those receiving TMP-SMX prophylaxis ( < 0.001).

CONCLUSION AND RELEVANCE

Our findings suggest that OI prophylaxis with TMP-SMX may be protective against nocardiosis in SOT recipients. If possible, patients who are switched to an alternative agent due to TMP-SMX intolerance should be re-challenged when the adverse effect resolves. Most patients in our study were able to tolerate re-initiation, suggesting that the adverse effects associated with TMP-SMX may be temporary and may not warrant discontinuation.

摘要

背景

甲氧苄啶 - 磺胺甲恶唑(TMP - SMX)是实体器官移植(SOT)后预防肺炎(肺孢子菌肺炎,PJP)和弓形虫病的首选药物。与其他药物相比,它对某些菌种还有额外的活性。

目的

本研究的目的是评估接受TMP - SMX或用于机会性感染(OI)预防的替代药物的SOT患者中诺卡菌病感染的发生率。

方法

这项回顾性分析纳入了一家大型城市医疗中心4年内的移植受者。所有患者均接受TMP - SMX或用于预防PJP的替代药物。主要结局是移植后24个月内诺卡菌病感染的发生率。次要结局包括诺卡菌分离株的耐药率、替代预防药物的使用率、使用替代药物的原因以及从替代药物换回TMP - SMX的转化率。

结果

共纳入791名接受PJP或弓形虫病预防的成年SOT受者。移植时的平均年龄为60.9岁,大多数患者为男性(67.3%),肺移植受者占63.6%。TMP - SMX是最常用的初始预防药物(84.6%),其次是阿托伐醌(15.4%)。在791名SOT受者中,16名(2.0%)在移植后24个月内被诊断为诺卡菌病。与接受TMP - SMX预防的患者相比,接受替代药物的患者感染发生率更高(P < 0.001)。

结论及意义

我们的研究结果表明,TMP - SMX预防OI可能对SOT受者预防诺卡菌病有保护作用。如果可能,因TMP - SMX不耐受而改用替代药物的患者,当不良反应消失时应重新尝试使用TMP - SMX。我们研究中的大多数患者能够耐受重新开始使用,这表明与TMP - SMX相关的不良反应可能是暂时的,可能无需停药。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验